ALNY · Alnylam Pharmaceuticals, Inc.
$247.51
-4.07% last session
End-of-day data · close of 2026-09-10
Market cap
$33B
Enterprise value
$33B
Trailing P/E
45.1
Forward P/E
19.9
Dividend yield
—
Beta
0.30
Avg volume
2M
Employees
2K
Daily Change %
-4.07%
5 Days Change
-3.05%
10 Days Change
7.19%
30 Days Change
16.64%
60 Days Change
-13.64%
Month to Day Change
4.83%
Year to Day Change
-35.12%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — ALNY
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-09-08
Latest call per bank · past 12 months
Jefferies
Hold$260
+5.0% vs priceWells Fargo
Equal-Weight$256
+3.4% vs priceCitigroup
Buy$340
+37.4% vs priceBarclays
Overweight$450
+81.8% vs priceJP Morgan
Overweight$375
+51.5% vs priceRBC Capital
Outperform$350
+41.4% vs priceMorgan Stanley
Equal-Weight$300
+21.2% vs priceBank of America
Buy$410
+65.6% vs priceGoldman Sachs
Buy$566
+128.7% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-09-08 | Jefferies | Maintains | Hold | $230 → $260 |
| 2026-09-02 | HC Wainwright & Co. | Reiterates | Buy | $455 |
| 2026-08-19 | BMO Capital | Initiates | Outperform | $0.00 → $318 |
| 2026-08-14 | Wells Fargo | Maintains | Equal-Weight | $316 → $256 |
| 2026-08-04 | Truist Securities | Maintains | Buy | $410 → $315 |
| 2026-08-04 | HC Wainwright & Co. | Maintains | Buy | $485 → $455 |
| 2026-08-03 | Raymond James | Upgrade | Outperform → Strong Buy | $420 |
| 2026-08-03 | Citigroup | Maintains | Buy | $380 → $340 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-09-10
- RSI (14): RSI is 50 — neutral momentum, neither overbought nor oversold.
- Price vs 50-day MA: Trading 3.5% below the 50-day MA ($256.42).
- Price vs 200-day MA: Trading 22.2% below the 200-day MA ($318.12).
- MA cross: The 50-day MA sits below the 200-day MA (death-cross regime) — the longer-term trend points down.
- MACD (12,26,9): MACD histogram is positive (+3.06) — short-term momentum is improving.
- 52-week range: Price sits between the 52-week low ($205.48) and high ($491.22).
ALNY Price Chart
Loading chart for ALNY…
Fundamentals
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally. The company offers ONPATTRO for hereditary transthyretin-mediated (hATTR) amyloidosis; AMVUTTRA for ATTR and hATTR amyloidosis; Leqvio for hypercholesterolemia; Qfitlia for hemophilia A or B; GIVLAARI for acute hepatic porphyria; and OXLUMO for primary hyperoxaluria type 1. It also develops a range of products in Phase 3 trial, such as Nucresiran for ATTR amyloidosis; Zilebesiran for hypertension; Cemdisiran for myasthenia gravis, paroxysmal nocturnal hemoglobinuria, and geographic atrophy; and Elebsiran for hepatitis D virus infections. In addition, the company is developing various products in Phase 2 trial, including Rapirosiran for metabolic dysfunction-associated steatohepatitis; ALN-ANG3 for diabetic kidney disease; ALN-4324 for type 2 diabetes mellitus; Mivelsiran for cerebral amyloid angiopathy, as well as in Phase 1 trial for Alzheimer's disease; and ALN-6400 for bleeding disorders. Further, it develops a range of products in Phase 1 trial, such as ALN-2232 for obesity and weight management; ALN-PNP for non-alcoholic fatty liver disease; ALN-APOC3 for dyslipidemia; ALN-CIDEB for metabolic dysfunction-associated steatohepatitis; ALN-HTT02 for Huntington's disease; ALN-5288 for Alzheimer's disease; ALN-SOD for SOD1 amyotrophic lateral sclerosis; ALN-SNCA for Parkinson's disease; AG-236 for polycythemia vera; ALN-CFB for paroxysmal nocturnal hemoglobinuria; ALN-BCAT for hepatocellular carcinoma; and ALN-4285, ALN-4915, and ALN-F1202 for healthy volunteers. The company has collaborations with Regeneron Pharmaceuticals, Inc.; Roche Holding AG; Sanofi S.A.; Novartis AG; PeptiDream, Inc; Dicerna Pharmaceuticals, Inc.; and Ionis Pharmaceuticals, Inc. Alnylam Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Cambridge, Massachusetts.
More in Biotechnology
VRTX
Vertex Pharmaceuticals Incorpor
$130B 14.9% YTD
REGN
Regeneron Pharmaceuticals, Inc.
$82B 5.0% YTD
ARGX
argenx SE
$62B 19.2% YTD
MRNA
Moderna, Inc.
$55B 359.9% YTD
RVMD
Revolution Medicines, Inc.
$44B 160.7% YTD
ONC
BeOne Medicines Ltd.
$39B 15.5% YTD
RPRX
Royalty Pharma plc
$34B 59.0% YTD
ROIV
Roivant Sciences Ltd.
$30B 92.7% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.